Drug Trial Radar · NCT01725802
A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) Patients
Last checked: Nov 19, 2026Latest source record: May 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Dec 16, 2012
Primary completion
Feb 26, 2013
Study completion Feb 26, 2013
Sponsor
- Lead sponsor
- NeuroDerm Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 14, 2012
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this Phase I/IIa study, the effect of continuous subcutaneous administration of LD/CD solution (ND0612) on the safety and PK profile of LD will be examined.
Conditions
- Parkinson's Disease
Interventions
Levodopa/carbidopa solution for SC administrationDrug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and frequency of adverse eventsTime frame: up to 8 weeks
- Withdrawal rateTime frame: 2 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hadassah Medical Center
Jerusalem, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.